Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817635 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00817635 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 155 participants.
The verdict
NCT00817635, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
Interventions
- DRUG LCI699
- DRUG Eplerenone
- DRUG LCI699-matching Placebo
- DRUG Eplerenone-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2008-12-22 |
| Est. Completion | 2009-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817635
The ClinicalTrials.gov registry entry for NCT00817635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LCI699 is the first listed.
NCT00817635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00817635 about?
NCT00817635 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension". This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
What is the current status of trial NCT00817635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2008-12-22. Estimated completion is 2009-10-13.
What interventions are being tested in trial NCT00817635?
The interventions under investigation include: LCI699 (DRUG), Eplerenone (DRUG), LCI699-matching Placebo (DRUG), Eplerenone-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT00817635?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.